source boundary
frontier-owneddeclared
A source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
frontiers / frontier
Source record
back to sourcessource boundary
frontier-ownedA source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
finding bindings
record contextFindings bound to this source through source ids, evidence atoms, provenance, or reviewed source-record slots.
evidence atoms
materializedEvidence atoms pin exact spans, measurements, selectors, or curation assertions to the source.
review context
inspectable1 reviewable changes and 0 evaluations are attached through this source or its findings.
Locator and citation
locator
title:Eggermont et al. NEJM 2018 (KEYNOTE-054 melanoma adjuvant); Felip et al. Lancet 2021 (IMpower010 NSCLC)
imported
2026-05-09T22:25:03.494622+00:00
extraction mode
manual_curation
authors
agent:immuno-research-bot-2026-05-09
Caveats
No source-specific caveats are recorded.
Adjuvant pembrolizumab after surgery in resected stage III melanoma reduced recurrence vs placebo; this established post-resection adjuvant immunotherapy as standard for high-risk melanoma. Adjuvant immunotherapy for completely resected NSCLC, RCC, and MIBC followed similar trial designs with positive results.
events
vev_6e994b8a9cbad998finding.assertedManual finding added to frontier state
agent:immuno-research-bot-2026-05-09 · 2026-05-09
reviewable changes
vpr_2e88c9e2af66eb5bfinding.addManual finding added to frontier state
applied · agent:immuno-research-bot-2026-05-09 · 2026-05-09
evaluations
No evaluation rows are attached.